Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Recruiting

Phase 2

Denikitug, Nivolumab, Ramucirumab, PaclitaxelStudy of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Sponsor:

Gilead Sciences

Code:

NCT07546812

Conditions

HER2-negative

Gastroesophageal Junction

Esophageal Adenocarcinoma

Gastric Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Denikitug

Nivolumab

Ramucirumab

Paclitaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-20. This information was provided to ClinicalTrials.gov by Gilead Sciences on 2026-07-10.